{"name":"Hutchison MediPharma","permalink":"hutchison-medipharma","crunchbase_url":"http://www.crunchbase.com/company/hutchison-medipharma","homepage_url":"http://www.hmplglobal.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"BD@hmplglobal.com","phone_number":"+86 21 5079 0088","description":"","created_at":"Thu Dec 30 02:00:58 UTC 2010","updated_at":"Wed Aug 15 18:30:12 UTC 2012","overview":"<p>Hutchison Medi Pharma is an entrepreneurial, China-based, global quality drug development company with a rich pipeline, strong R&amp;D leadership and a proven track record.</p>\n\n<p>We are a novel drug R&amp;D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and immunology.  With a team of around 200 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and China.</p>\n\n<p>These products include a novel oral compound for inflammatory bowel disease, which is entering Phase III for UC (ulcerative colitis) in the US &amp; Europe; a novel oral selective c-Met inhibitor in phase I in Australia; three differentiated oral NCEs in oncology in Phase I in China and one NCE entering Phase I soon.  Multiple NCEs are also in preclinical development.</p>\n\n<p>After founding the company in 2002, we have built one of the largest and most experienced new drug R&amp;D teams in China.  We are led by a strong senior management team, all of whom have many years of experience succeeding at large US pharmaceutical and biotech companies. Our strategic partnerships have involved global, innovative companies such as AstraZeneca, Johnson &amp; Johnson, Eli Lilly and Merck Serono in both oncology and inflammation.</p>","image":{"available_sizes":[[[150,50],"assets/images/resized/0011/5778/115778v1-max-150x150.png"],[[180,60],"assets/images/resized/0011/5778/115778v1-max-250x250.png"],[[180,60],"assets/images/resized/0011/5778/115778v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[{"is_past":true,"title":"CEO","person":{"first_name":"Samantha","last_name":"Du","permalink":"samantha-du","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$20.2M","funding_rounds":[{"round_code":"unattributed","source_url":"http://www.hmplglobal.com/en/news_show.asp?id=59","source_description":"Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline ","raised_amount":12500000,"raised_currency_code":"USD","funded_year":2010,"funded_month":11,"funded_day":8,"investments":[{"company":{"name":"Mitsui & Co","permalink":"mitsui","image":{"available_sizes":[[[150,18],"assets/images/resized/0008/9308/89308v1-max-150x150.png"],[[249,30],"assets/images/resized/0008/9308/89308v1-max-250x250.png"],[[249,30],"assets/images/resized/0008/9308/89308v1-max-450x450.png"]],"attribution":null}},"financial_org":null,"person":null}]},{"round_code":"unattributed","source_url":"https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29&aid=DJFVLS0020101222e6cm0005n&r=Rss&s=DJFVLS","source_description":"Hutchison MediPharma Gains Funding From SB China","raised_amount":7700000,"raised_currency_code":"USD","funded_year":2010,"funded_month":12,"funded_day":21,"investments":[{"company":null,"financial_org":{"name":"SBCVC Fund III Company","permalink":"sbcvc-fund-iii-company","image":null},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"Building 4, 720 Cailun Road","address2":"Zhangjiang Hi-Tech Park","zip_code":"201203","city":"Shanghai","state_code":null,"country_code":"CHN","latitude":null,"longitude":null}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}